Interpreting Genomic Variation: Inherited Cancer Susceptibility
Explore germline variation in cancer susceptibility genes
Germline genomic variation can increase the risk of developing cancer. It’s essential to use the best evidence available to decide if a genomic variant is likely to increase the chance of a person developing cancer. This allows us to offer at-risk individuals access to appropriate screening, prevention, and personalised treatments.
Learn how to interpret genes for susceptibility to cancer
On this course, you will consider how variant interpretation in cancer susceptibility genes has different considerations when compared with variant interpretation in rare paediatric disease.
You’ll explore the guidelines produced by the UK Cancer Variant Interpretation Group (CanVIG-UK) for variant interpretation and how these can be applied to the American College of Medical Genetics (ACMG) framework in the classification of germline variants in cancer susceptibility genes.
Study the CanVIG-UK guidelines in theory and practice
This course will provide you with patient examples to explore the complexities of variant interpretation in cancer genomics. You’ll also hear from experts in the field about how the CanVIG-UK guidance was created.
You’ll be encouraged to apply your learning through case-based exercises that illustrate both the strengths and weaknesses of the tools and guidelines available for cancer variant interpretation.
Study with world-leading genomic experts at St George’s
Learn from Professor Kate Tatton-Brown and Dr Katie Snape – renowned consultant Clinical Geneticists leading on variant interpretation for rare disease and cancer.
This course is part of a series with Interpreting Genomic Variation: Fundamental Principles.
- Inherited genetic variation in familial cancer syndromes.
- Tools for variant interpretation and how these are applied to the interpretation of cancer susceptibility gene variation.
- The application of the ACMG framework to inherited cancer.
- The implementation of a clinical framework to embed cancer susceptibility gene interpretation into clinical practice.
Learning on this course
On every step of the course you can meet other learners, share your ideas and join in with active discussions in the comments.
What will you achieve?
By the end of the course, you‘ll be able to...
- Describe the importance of large scale collaborative infrastructure to standardise evidence based variant interpretation in cancer susceptibility genes
- Apply the CanVIG-UK guidelines for variant interpretation to classify variants in cancer susceptibility genes involved in hereditary breast and ovarian cancer and Lynch Syndrome
- Assess the strengths and weaknesses of the American College of Medical Genetics (ACMG) guidelines for variant interpretation in complex disease, such as cancer, compared to rare paediatric disease
- Explore the different ways in which cancer susceptibility gene variant interpretation can impact on patient care
- Assess the complexities of applying cancer susceptibility gene variant interpretation in clinical practice including the implications of reduced penetrance variants and potential changes in classifications over time
Who is the course for?
This course would be suitable for:
• Clinical Genetics doctors (consultant and specialist registrars) • Clinical Scientists • Genetic Counsellors • Clinical Oncology doctors (consultants and specialist registrars) • Pathologists undertaking cancer MDTs • Specialist oncology nurses undertaking genetic testing
Do you know someone who'd love this course? Tell them about it...
Learners who joined this course have also enjoyed these courses.